Evidence map›Paper›PMID 27825154›Full record

ReviewCells, tissues, organs2016

Growth Factors for Skeletal Muscle Tissue Engineering.

Brian C Syverud, Keith W VanDusen, Lisa M Larkin

Open access · bronzeAbstract readReview
In one paragraph

Review in Cells, tissues, organs, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 74 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Aligned Collagen Sponges Loaded With Myogenic Factors to Enhance Skeletal Muscle Tissue Regeneration.Journal of biomedical materials research. Part B, Applied biomaterials · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Development of a Chemically Defined Medium forFrontiers in bioengineering and biotechnology · 2022
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Brian C Syverud
Keith W VanDusen
Lisa M Larkin
University of Michigan · US

Funding

Microfluidics in Biomedical Sciences Training ProgramT32EB005582 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FAN, XUDONG · 2005 to 2020
$3.9M
Utilization of Engineered Skeletal Muscle Units to Repair Volumetric MuscleR01AR067744 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LARKIN, LISA M · 2015 to 2019
$2.3M
Engineering Innervated Muscle-Tendon Constructs for Tissue RegenerationR01AR054778 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LARKIN, LISA M · 2007 to 2011
$1.7M
Utilization of Engineered Skeletal Muscle Units to Repair Volumetric Muscle LossR56AR054778 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LARKIN, LISA M · 2014 to 2014
$156k
NIAMS NIH HHS R01 AR054778NIAMS NIH HHS R01 AR067744NIAMS NIH HHS R56 AR054778NIBIB NIH HHS T32 EB005582
6 · The paper itself

Abstract

Tissue-engineered skeletal muscle holds promise as a source of graft tissue for repair of volumetric muscle loss and as a model system for pharmaceutical testing. To reach this potential, engineered tissues must advance past the neonatal phenotype that characterizes the current state of the art. In this review, we describe native skeletal muscle development and identify important growth factors controlling this process. By comparing in vivo myogenesis to in vitro satellite cell cultures and tissue engineering approaches, several key similarities and differences that may potentially advance tissue-engineered skeletal muscle were identified. In particular, hepatocyte and fibroblast growth factors used to accelerate satellite cell activation and proliferation, followed by addition of insulin-like growth factor as a potent inducer of differentiation, are proven methods for increased myogenesis in engineered muscle. Additionally, we review our recent novel application of dexamethasone (DEX), a glucocorticoid that stimulates myoblast differentiation, in skeletal muscle tissue engineering. Using our established skeletal muscle unit (SMU) fabrication protocol, timing- and dose-dependent effects of DEX were measured. The supplemented SMUs demonstrated advanced sarcomeric structure and significantly increased myotube diameter and myotube fusion compared to untreated controls. Most significantly, these SMUs exhibited a fivefold rise in force production. Thus, we concluded that DEX may serve to improve myogenesis, advance muscle structure, and increase force production in engineered skeletal muscle.

Indexed as

AnimalsHumansIntercellular Signaling Peptides and ProteinsMuscle DevelopmentMuscle, SkeletalRegenerationSatellite Cells, Skeletal MuscleTissue EngineeringIntercellular Signaling Peptides and Proteins

Identifiers

PMID27825154
PMCPMC5130097
OpenAlexW2550220631

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.